triptolide has been researched along with Lymphoma, Primary Effusion in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Guo, W; Liu, Y; Long, C; Sun, X; Wang, C; Wang, H; Wang, J | 1 |
Guo, W; Long, C; Sun, X; Wang, H; Wang, J; Zhou, H | 1 |
2 other study(ies) available for triptolide and Lymphoma, Primary Effusion
Article | Year |
---|---|
Triptolide inhibits transcription of hTERT through down-regulation of transcription factor specificity protein 1 in primary effusion lymphoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Diterpenes; Down-Regulation; Epoxy Compounds; Humans; Lymphoma, Primary Effusion; Phenanthrenes; Sp1 Transcription Factor; Telomerase; Transcriptional Activation | 2016 |
Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells.
Topics: Animals; Antigens, Viral; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Down-Regulation; Epoxy Compounds; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; Herpesvirus 8, Human; Humans; Lymphoma, Primary Effusion; Mice; Nuclear Proteins; Phenanthrenes; Sarcoma, Kaposi; STAT3 Transcription Factor; Viral Load; Xenograft Model Antitumor Assays | 2016 |